Journal
CELL METABOLISM
Volume 17, Issue 5, Pages 768-778Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2013.04.012
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [DK064360]
- NIH Roadmap [DK71507-04]
- American Diabetes Association
- NIH [R90 DK071507]
- Manpei Suzuki Diabetes Foundation
- Japan Society for the Promotion of Science
- Grants-in-Aid for Scientific Research [23591106] Funding Source: KAKEN
Ask authors/readers for more resources
Proper control of hepatic glucose production is central to whole-body glucose homeostasis, and its disruption plays a major role in diabetes. Here, we demonstrate that although established as an intracellular lipid chaperone, aP2 is in fact actively secreted from adipocytes to control liver glucose metabolism. Secretion of aP2 from adipocytes is regulated by fasting-and lipolysis-related signals, and circulating aP2 levels are markedly elevated in mouse and human obesity. Recombinant aP2 stimulates glucose production and gluconeogenic activity in primary hepatocytes in vitro and in lean mice in vivo. In contrast, neutralization of secreted aP2 reduces glucose production and corrects the diabetic phenotype of obese mice. Hyperinsulinemic-euglycemic and pancreatic clamp studies upon aP2 administration or neutralization demonstrated actions of aP2 in liver. We conclude that aP2 is an adipokine linking adipocytes to hepatic glucose production and that neutralizing secreted aP2 may represent an effective therapeutic strategy against diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available